The impact of online CME on addressing clinical decision-making for immunotherapy in advanced squamous NSCLC.

e21002 Background: Immunotherapy (IO)-based regimens are foundational to the management of advanced squamous non-small cell lung cancer (NSCLC). Effective clinical application requires accurate interpretation of emerging trial data, integration of patient- and disease-specific considerations, and informed selection among available regimens. Given the multidisciplinary nature of NSCLC care, baseline understanding and practical readiness to apply immunotherapy data may vary across oncologists, pathologists, and pulmonologists. The objective of this study was to assess the educational impact of a single continuing medical education (CME) activity on clinicians’ recognition of the role of IO in advanced squamous NSCLC and treatment decisions. Methods: The educational intervention presented included an online, CME-certified video discussion between two expert faculty. Educational impact was assessed with repeated paired pre-/post-assessment study design, where individual participants served as their own control. Outcomes were analyzed by learning objective and stratified by specialty (oncologists, pathologists, and pulmonologists). A McNemar’s test assessed significant levels of changes reported with P values <.05 considered statistically significant. The activity launched September 2025; data were collected until January 2026. Results: Across specialties, participation in CME was associated with improvements in post-education performance (Table). Exploratory analyses demonstrated that frequency of clinical encounters with patients with advanced squamous NSCLC did not meaningfully influence baseline knowledge or degree of improvement. Conclusions: This analysis demonstrates variable baseline preparedness and distinct, specialty-specific educational needs related to IO use in advanced squamous NSCLC. While education improved understanding of clinical evidence and disease-specific considerations, gaps in translating data into regimen selection persisted for some audiences, reinforcing the need for ongoing, targeted educational strategies. Importantly, improvements were not dependent on patient volume or experience, suggesting that structured education can benefit clinicians regardless of prior exposure to this patient population. Learning Objective Oncologists (N = 35) (% Pre Correct, % Post Correct; P Value) Pulmonologists (N = 20) (% Pre Correct, % Post Correct; P Value) Pathologists (N = 43) (% Pre Correct, % Post Correct; P Value) Describe the clinical considerations associated with advanced squamous NSCLC 93%, 96%; NS 78%, 90%; NS 63%, 79%; <.01 Differentiate between key findings of immunotherapy use in advanced squamous NSCLC 61%, 77%; <.001 50%, 80%; <.01 48%, 64%; <.01 Articulate the rationale for selecting specific immunotherapy regimens for advanced squamous NSCLC 31%, 54%; <.01 5%, 15%; NS 7%, 9%; NS